Compare Axogen Inc (AXGN) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Estee Lauder Companies Inc — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Estee Lauder Companies Inc trades at $87.54 (market cap $31.76B). The key difference: Estee Lauder Companies Inc is far larger — about 12.2× Axogen Inc's market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | EL | |
|---|---|---|
Market Cap | $2.61B | $31.76B |
Sector | Technology | Consumer Staples |
52-Week High | $48.48 | $119.61 |
52-Week Low | $14.16 | $67.23 |
Enterprise Value | $2.52B | $37.93B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
EL trades at $87.70, up 0.58% on the day, with a bullish technical signal from moving averages and a consensus price target of $91.67. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.13 billion for 2025. Revenue has declined from $17.7 billion in 2022 to $14.33 billion in 2025, but positive cash flow from operations of $1.27 billion provides liquidity. A new fragrance launch and executive appointment signal ongoing brand development efforts.
The stock presents a mixed outlook. Analyst sentiment is divided with a slight Hold bias, yet technical momentum and earnings beats offer near-term upside potential. Key risks include sustained negative net income margins, high debt levels, and competitive pressures in the beauty sector. The upcoming Q2 2026 earnings report on August 19, 2026, will be critical for validating the recent positive earnings trend and guiding future price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
